Results Release and Webinar Discussion on Morning of December 18, 2025MISSISSAUGA, Ontario, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its fourth quarter of fiscal 2025 ended September 30, 2025 (“Q4 2025”) prior to the start of trading on December 18, 2025. At 10:00 AM ET that d ...

Core Insights - Microbix Biosystems Inc. is addressing a cybersecurity incident involving a ransomware attack that resulted in data theft but did not disrupt operations [1][2][3] - The company has been enhancing its cybersecurity measures since early 2022, including the implementation of advanced software systems [4][8] - Microbix has a policy of not paying ransoms to hackers, aiming to discourage cybercrime [4] Company Overview - Microbix is a life sciences innovator focused on creating proprietary biological products for human health, with over 120 employees and monthly revenues targeting C$ 2.0 million or more [5][6] - The company manufactures critical ingredients for the global diagnostics industry, including antigens for immunoassays and quality assessment products [5] - Microbix's products are sold in over 30 countries and are supported by a network of international distributors [5] Cybersecurity Measures - The company has adopted the Center for Internet Security (CIS) frameworks for its cybersecurity programs [8] - Regular employee cybersecurity training and endpoint server protection for real-time threat monitoring are part of the ongoing improvements [8] - Microbix is also focusing on disaster-recovery and business-continuity planning [8]

Core Insights - Microbix Biosystems Inc. hosted Ontario's Minister of Public and Business Service Delivery and Procurement, Stephen Crawford, to showcase its biotechnology facilities and discuss advancements in diagnostics that can enhance health outcomes and reduce healthcare costs for Ontarians [1][2] - The company has received over C$ 2.0 million in grant funding from the Ontario Together Funds, which has supported the development of state-of-the-art manufacturing capabilities and healthcare products [1][3] - Microbix supplied over 2 million units of Viral Transport Medium (VTM) to Ontario during the pandemic years of 2021 and 2022, including a significant emergency order of 1.2 million units in December 2021 [1] Company Overview - Microbix is an Ontario-based life sciences innovator with over 120 skilled employees, producing proprietary biological products for human health [3][4] - The company manufactures critical ingredients for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products (QAPs™) [3] - Microbix's products are distributed in over 30 countries and are supported by a network of international distributors, with various accreditations including ISO 9001 & 13485 and U.S. FDA registration [3][4] Product Development - Microbix develops proprietary products such as Kinlytic urokinase, a thrombolytic drug for treating blood clots, and reagents for molecular diagnostic testing [4] - The company emphasizes its commitment to innovation and the development of Ontario-made products that contribute to global health [2][3]

Company Overview - Microbix Biosystems Inc. is a life sciences innovator, manufacturer, and exporter, focusing on proprietary biological products for human health [4] - The company has over 120 skilled employees and aims for revenues of C$ 2.0 million or more per month [4] - Microbix specializes in critical ingredients and devices for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products (QAPs™) [4][5] Product and Service Offerings - Microbix's antigens support antibody tests for approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs [4] - The company also develops proprietary products such as Kinlytic, a biologic thrombolytic drug for treating blood clots, and reagents for molecular diagnostic testing [5] Conference Participation - Microbix will attend and present at the 2025 Bloom Burton & Co. Healthcare Investor Conference on May 5 & 6, 2025 [1][2] - CEO Cameron Groome will present to investors on May 6 at 2:30 p.m. Eastern Time, and senior management will engage in one-on-one meetings with investors [2] Industry Context - The Bloom Burton & Co. Conference aims to connect investors with developments in the Canadian healthcare and life sciences sector [2][3] - Bloom Burton & Co. provides capital raising, M&A advisory, equity research, and strategic advisory services to accelerate returns in the healthcare sector [3]